SCHEMBL3249879

SCHEMBL3249879

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(-c4ccc(Cl)nc4)cc3c12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 10/20 0.42
JAK3 P52333 10/20 0.42
NPC1 O15118 1/20 0.42
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
CSF1R P07333 1/20 0.41
GABRB1 P18505 1/20 0.40
GABRA3 P34903 1/20 0.40
CLEC4M Q9H2X3 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3254800 0.88 RIOK2 (0.46) JAK2JAK3NPC1GABRA1GABRB2
SCHEMBL3246162 0.85 TLR8 (0.37) NPC1GABRA1GABRB2CSF1RGABRB1
SCHEMBL3250069 0.85 GRIK1 (0.42) JAK2NPC1HSD17B10CYP1A2
SCHEMBL3250231 0.85 MMP2 (0.55) JAK2JAK3NPC1GABRA1GABRB2
SCHEMBL3252757 0.84 NPC1 (0.51) JAK2JAK3NPC1GABRA1GABRB2
SCHEMBL3249649 0.83 JAK2 (0.50) JAK2JAK3NPC1GABRA1GABRB2
SCHEMBL3250598 0.82 JAK2 (0.50) JAK2JAK3NPC1GABRA1GABRB2
SCHEMBL3243112 0.82 CSF1R (0.46) JAK2JAK3NPC1GABRA1GABRB2
SCHEMBL3252802 0.82 GABRA1 (0.43) JAK2JAK3NPC1GABRA1GABRB2
SCHEMBL3250086 0.82 JAK2 (0.52) JAK2JAK3NPC1GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 JAK2 70/4885JAK3 171/4885NPC1 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.